Although further research is required to delineate the precise mechanism of action underlying the clinical activity observed with the combination of vorinostat, lenalidomide and dexamethasone, interesting results have been seen with other HDAC combinations in the treatment of MM. This evidence concerns the gene HDAC9 and Miyoshi myopathy.